Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines – Heart Failure Registry
Journal of Cardiac Failure · 2024
DOI: 10.1016/j.cardfail.2023.09.005 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Cardiac Failure, 2024. Verfasst von Ankeet S Bhatt und 18 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente San Francisco Medical Center and Division of Research, Oakland, CA; Division of Cardiovascular Medicine, Brigham and Women's Hospit…. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus, Metformin. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, National Institutes of Health.
Themen: Herzinsuffizienz, Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Patients hospitalized with heart failure (HF) and diabetes mellitus (DM) are at risk for worsening clinical status. Little is known about the frequency of therapeutic changes during hospitalization. We characterized the use of medical therapies before, during and after hospitalization in patients with HF and DM. METHODS: We identified Medicare beneficiaries in Get With The Guidelines-Heart Failure (GWTG-HF) hospitalized between July 2014 and September 2019 with Part D prescription coverage. We evaluated trends in the use of 7 classes of antihyperglycemic therapies (metformin, sulfonylureas, GLP-1RA, SGLT2-inhibitors, DPP-4 inhibitors, thiazolidinediones, and insulins) and 4 classes of HF therapies (evidence-based β-blockers, ACEi or ARB, MRA, and ARNI). Medication fills were assessed at 6 and 3 months before hospitalization, at hospital discharge and at 3 months post-discharge. RESULTS: Among 35,165 Medicare beneficiaries, the median age was 77 years, 54% were women, and 76% were white; 11,660 (33%) had HFrEF (LVEF ≤ 40%), 3700 (11%) had HFmrEF (LVEF 41%-49%), and 19,805 (56%) had HFpEF (LVEF ≥ 50%). Overall, insulin was the most commonly prescribed antihyperglycemic after HF hospitalization (n = 12,919, 37%), followed by metformin (n = 7460, 21%) and sulfonylureas (n = 7030, 20%). GLP-1RA (n = 700, 2.0%) and SGLT2i (n = 287, 1.0%) use was low and did not improve over time. In patients with HFrEF, evidence-based beta-blocker, RASi, MRA, and ARNI fills during the 6 months preceding HF hospitalization were 63%, 62%, 19%, and 4%, respectively. Fills initially declined prior to hospitalization, but then rose from 3 months before hospitalization to discharge (beta-blocker: 56%-82%; RASi: 51%-57%, MRA: 15%-28%, ARNI: 3%-6%, triple therapy: 8%-20%; P < 0.01 for all). Prescription rates 3 months after hospitalization were similar to those at hospital discharge. CONCLUSIONS: In-hospital optimization of medical therapy in patients with HF and DM is common in participating hospitals of a large US quality improvement registry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente San Francisco Medical Center and Division of Research, Oakland, CA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, Los Angeles, CA.
- Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Durham, NC.
- Duke Clinical Research Institute, Durham, NC.
- Baylor Scott and White Research Institute, Dallas, Texas.
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA.
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- National Institutes of Health
- National Institute of Nursing Research
- U.S. Food and Drug Administration
- American Heart Association
- AstraZeneca Pharmaceuticals LP
- National Institute on Aging
Zitieren
APA
Bhatt, A. S., Fonarow, G. C., Greene, S. J., Holmes, D. N., Alhanti, B., Devore, A. D., Butler, J., Heidenreich, P. A., Huang, J. C., Kittleson, M. M., Linganathan, K., Joyntmaddox, K. E., McDermott, J. J., Owens, A. T., Peterson, P. N., Solomon, S. D., Vardeny, O., Yancy, C. W., & Vaduganathan, M. (2024). Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines – Heart Failure Registry. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2023.09.005
Vancouver
Bhatt AS, Fonarow GC, Greene SJ, Holmes DN, Alhanti B, Devore AD, et al. Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines – Heart Failure Registry. Journal of Cardiac Failure. 2024. doi:10.1016/j.cardfail.2023.09.005
BibTeX
@article{Bhatt2024,
author = {Bhatt, Ankeet S and Fonarow, Gregg C and Greene, Stephen J and Holmes, Dajuanicia N and Alhanti, Brooke and Devore, Adam D and Butler, Javed and Heidenreich, Paul A and Huang, Joanna C and Kittleson, Michelle M and Linganathan, Karthik and Joyntmaddox, Karen E and McDermott, James J and Owens, Anjali Tiku and Peterson, Pamela N and Solomon, Scott D and Vardeny, Orly and Yancy, Clyde W and Vaduganathan, Muthiah},
title = {Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines – Heart Failure Registry},
journal = {Journal of Cardiac Failure},
year = {2024},
doi = {10.1016/j.cardfail.2023.09.005}
}
EUVIMED